$CORT
Corcept Therapeutics Inc

2021 Q2 Form 10-Q Financial Statement

#000162828021014900 Filed on July 29, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $91.59M $88.57M
YoY Change 3.41% 22.57%
Cost Of Revenue $1.384M $1.234M
YoY Change 12.16% -10.38%
Gross Profit $90.20M $87.33M
YoY Change 3.29% 23.21%
Gross Profit Margin 98.49% 98.61%
Selling, General & Admin $30.03M $25.57M
YoY Change 17.43% 3.99%
% of Gross Profit 33.29% 29.28%
Research & Development $28.23M $26.50M
YoY Change 6.55% 22.35%
% of Gross Profit 31.3% 30.34%
Depreciation & Amortization $214.0K $200.0K
YoY Change 7.0% 0.0%
% of Gross Profit 0.24% 0.23%
Operating Expenses $58.26M $52.07M
YoY Change 11.89% 12.59%
Operating Profit $31.94M $35.26M
YoY Change -9.41% 43.15%
Interest Expense $110.0K $1.010M
YoY Change -89.11% -14.41%
% of Operating Profit 0.34% 2.86%
Other Income/Expense, Net $110.0K $1.010M
YoY Change -89.11% -14.26%
Pretax Income $32.05M $36.27M
YoY Change -11.63% 40.53%
Income Tax $5.500M $7.900M
% Of Pretax Income 17.16% 21.78%
Net Earnings $26.52M $28.33M
YoY Change -6.37% 40.33%
Net Earnings / Revenue 28.96% 31.98%
Basic Earnings Per Share $0.23 $0.25
Diluted Earnings Per Share $0.21 $0.23
COMMON SHARES
Basic Shares Outstanding 116.3M shares 115.0M shares
Diluted Shares Outstanding 126.7M shares 123.2M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $370.0M $405.4M
YoY Change -8.74% 101.19%
Cash & Equivalents $95.43M $58.52M
Short-Term Investments $274.6M $346.8M
Other Short-Term Assets $8.999M $5.300M
YoY Change 69.79% -14.52%
Inventory $4.669M $4.927M
Prepaid Expenses
Receivables $27.62M $22.73M
Other Receivables $0.00 $0.00
Total Short-Term Assets $411.3M $438.3M
YoY Change -6.17% 88.4%
LONG-TERM ASSETS
Property, Plant & Equipment $1.414M $619.0K
YoY Change 128.43% -47.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $101.7M $4.200M
YoY Change 2320.4% -82.64%
Other Assets $4.140M $4.536M
YoY Change -8.73% 2924.0%
Total Long-Term Assets $157.2M $59.49M
YoY Change 164.26% -38.05%
TOTAL ASSETS
Total Short-Term Assets $411.3M $438.3M
Total Long-Term Assets $157.2M $59.49M
Total Assets $568.5M $497.8M
YoY Change 14.19% 51.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.216M $6.304M
YoY Change 46.19% -10.28%
Accrued Expenses $21.51M $22.63M
YoY Change -4.94% 37.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $45.40M $42.24M
YoY Change 7.48% 39.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $403.0K $1.900M
YoY Change -78.79% 850.0%
Total Long-Term Liabilities $403.0K $1.900M
YoY Change -78.79% 850.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $45.40M $42.24M
Total Long-Term Liabilities $403.0K $1.900M
Total Liabilities $45.81M $44.13M
YoY Change 3.81% 44.08%
SHAREHOLDERS EQUITY
Retained Earnings $132.4M $34.84M
YoY Change 280.18% -143.94%
Common Stock $554.3M $481.8M
YoY Change 15.04% 10.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares 9.500M shares
Shareholders Equity $522.7M $453.7M
YoY Change
Total Liabilities & Shareholders Equity $568.5M $497.8M
YoY Change 14.19% 51.46%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income $26.52M $28.33M
YoY Change -6.37% 40.33%
Depreciation, Depletion And Amortization $214.0K $200.0K
YoY Change 7.0% 0.0%
Cash From Operating Activities $44.36M $53.20M
YoY Change -16.61% 108.63%
INVESTING ACTIVITIES
Capital Expenditures -$145.0K -$100.0K
YoY Change 45.0% -75.0%
Acquisitions
YoY Change
Other Investing Activities $24.90M -$85.90M
YoY Change -128.99% 10637.5%
Cash From Investing Activities $24.76M -$85.90M
YoY Change -128.82% 7709.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -26.08M 6.800M
YoY Change -483.51% -142.77%
NET CHANGE
Cash From Operating Activities 44.36M 53.20M
Cash From Investing Activities 24.76M -85.90M
Cash From Financing Activities -26.08M 6.800M
Net Change In Cash 43.04M -25.90M
YoY Change -266.18% -404.71%
FREE CASH FLOW
Cash From Operating Activities $44.36M $53.20M
Capital Expenditures -$145.0K -$100.0K
Free Cash Flow $44.51M $53.30M
YoY Change -16.5% 105.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001088856
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-50679
dei Entity Registrant Name
EntityRegistrantName
CORCEPT THERAPEUTICS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0487658
dei Entity Address Address Line1
EntityAddressAddressLine1
149 Commonwealth Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
327-3270
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
CORT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
115926629 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95430000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76190000 USD
CY2021Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
274552000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
364506000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27620000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26198000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
4669000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
4910000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8999000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6697000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
411270000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
478501000 USD
CY2021Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
14734000 USD
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
16247000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1524000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2509000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1414000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1675000 USD
CY2021Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
101657000 USD
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
36196000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4140000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5000000 USD
CY2021Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
33741000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
31603000 USD
CY2021Q2 us-gaap Assets
Assets
568480000 USD
CY2020Q4 us-gaap Assets
Assets
571731000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
9216000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10554000 USD
CY2021Q2 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
13113000 USD
CY2020Q4 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
13704000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21514000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21186000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1559000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2050000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
45402000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
47494000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
501000 USD
CY2021Q2 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
403000 USD
CY2020Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
398000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
45805000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
48393000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
125000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
122000 USD
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
554154000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
516140000 USD
CY2021Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
164263000 USD
CY2020Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
75795000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
215000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
415000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
132444000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52620000 USD
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30029000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
82456000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
522675000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
523338000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
568480000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
571731000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
91588000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
88565000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
171025000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
181812000 USD
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1384000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1234000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2652000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3112000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28232000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26497000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57254000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25572000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
59538000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
53107000 USD
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
59645000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
53303000 USD
us-gaap Costs And Expenses
CostsAndExpenses
119444000 USD
us-gaap Costs And Expenses
CostsAndExpenses
108839000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
31943000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
35262000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
51581000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
72973000 USD
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
110000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1010000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
385000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2481000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
32053000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
36272000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
51966000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
75454000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5530000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7945000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1978000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17062000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
26523000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
28327000 USD
us-gaap Net Income Loss
NetIncomeLoss
49988000 USD
us-gaap Net Income Loss
NetIncomeLoss
58392000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
16000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-170000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
77000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-190000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
545000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-242000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
606000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
16000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
42000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
26489000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
28857000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
49788000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
58971000 USD
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.51
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116294000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115006000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116555000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114790000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126680000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123234000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128204000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122756000 shares
us-gaap Profit Loss
ProfitLoss
49988000 USD
us-gaap Profit Loss
ProfitLoss
58392000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
21169000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
16407000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2061000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
10017000 USD
cort Accretion Expense Income
AccretionExpenseIncome
2471000 USD
cort Accretion Expense Income
AccretionExpenseIncome
-72000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1422000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2797000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1858000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
514000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
362000 USD
cort Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
985000 USD
cort Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
749000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-148000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1414000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2047000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-721000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-860000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1088000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1304000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1251000 USD
cort Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
-591000 USD
cort Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
4812000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
333000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-628000 USD
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-992000 USD
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-731000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
69761000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
86455000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
245000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
89000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
244971000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
153193000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
223268000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
219314000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21458000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66210000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
8786000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7347000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10142000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
62711000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
275000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
18054000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
63000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-71979000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7009000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19240000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27254000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76190000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31269000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95430000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58523000 USD
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
7704000 USD
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
772000 USD
cort Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability
NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
0 USD
cort Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability
NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
775000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
371182000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
480000 USD
CY2020Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
275000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7988000 USD
CY2020Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
49000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
30065000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
409489000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7639000 USD
CY2020Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
835000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8548000 USD
CY2020Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
530000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
28327000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
453698000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
523338000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10083000 USD
CY2021Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
33540000 USD
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
22520000 USD
CY2021Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-166000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
23465000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
510802000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6661000 USD
CY2021Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
29170000 USD
CY2021Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
3238000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11131000 USD
CY2021Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-34000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
26523000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
522675000 USD
cort Number Of Series Of Selective Cortisol Modulators
NumberOfSeriesOfSelectiveCortisolModulators
4 series
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2700000 shares
CY2021Q2 cort Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
0 USD
CY2020Q4 cort Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
1685000 USD
CY2021Q2 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
14379000 USD
CY2020Q4 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
12916000 USD
CY2021Q2 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
5024000 USD
CY2020Q4 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
6556000 USD
CY2021Q2 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
19403000 USD
CY2020Q4 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
21157000 USD
CY2021Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
14734000 USD
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
16247000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
4669000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
4910000 USD
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3781000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3528000 USD
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2367000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1853000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1414000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1675000 USD
cort Number Of Stock Option Plans
NumberOfStockOptionPlans
2 stockOptionPlan
CY2021Q2 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
10638000 USD
CY2020Q4 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
9412000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7740000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10144000 USD
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
760000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
151000 USD
CY2021Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
729000 USD
CY2020Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
665000 USD
CY2021Q2 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
670000 USD
CY2020Q4 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
612000 USD
CY2021Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
665000 USD
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
0 USD
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
312000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
202000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21514000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21186000 USD
CY2021Q2 cort Deposits For Clinical Trials
DepositsForClinicalTrials
3900000 USD
CY2020Q4 cort Deposits For Clinical Trials
DepositsForClinicalTrials
4800000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
445512000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
451226000 USD
CY2021Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
1400000 USD
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1300000 USD
cort Marketable Securities Maximum Maturity Period
MarketableSecuritiesMaximumMaturityPeriod
P2Y
cort Marketable Securities Weighted Average Maturity Period
MarketableSecuritiesWeightedAverageMaturityPeriod
P8M
CY2021Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 USD
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0 USD
CY2021Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
900000 shares
CY2021Q2 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
100000 shares
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
1000000.0 shares
CY2021Q2 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1600000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
18100000 USD
CY2020Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1000000.0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1100000 shares
CY2020Q2 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
100000 shares
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
100000 shares
CY2020Q2 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
100000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
100000 USD
CY2021Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
9500000 shares
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5900000 shares
CY2021Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
63000 USD
CY2020Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
59000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
104000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
129000 USD
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
11131000 USD
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
8548000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
21273000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
16536000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
26523000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
28327000 USD
us-gaap Net Income Loss
NetIncomeLoss
49988000 USD
us-gaap Net Income Loss
NetIncomeLoss
58392000 USD
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116294000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115006000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116555000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114790000 shares
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10386000 shares
CY2020Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8228000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
11649000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7966000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126680000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123234000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128204000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122756000 shares
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.51
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26000000.0 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26400000 shares
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5500000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000000.0 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7900000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17100000 USD
CY2021Q2 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
600000 USD
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
800000 USD
CY2021Q2 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
6700000 USD
CY2021Q2 cort Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance
UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance
1600000 USD

Files In Submission

Name View Source Status
0001628280-21-014900-index-headers.html Edgar Link pending
0001628280-21-014900-index.html Edgar Link pending
0001628280-21-014900.txt Edgar Link pending
0001628280-21-014900-xbrl.zip Edgar Link pending
cort-20210630.htm Edgar Link pending
cort-20210630.xsd Edgar Link pending
cort-20210630_cal.xml Edgar Link unprocessable
cort-20210630_def.xml Edgar Link unprocessable
cort-20210630_htm.xml Edgar Link completed
cort-20210630_lab.xml Edgar Link unprocessable
cort-20210630_pre.xml Edgar Link unprocessable
cort63021ex311.htm Edgar Link pending
cort63021ex312.htm Edgar Link pending
cort63021ex321.htm Edgar Link pending
cort63021ex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending